Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

2 Dividend Kings Yielding Around 3% to Grab Now

High yields aren't the only reason to buy shares of dividend-paying stocks. For investors seeking quality dividend stocks for passive income, here's a look at two companies with long track records of raising shareholder payouts.

Barchart

Apple's board of directors welcomes space program expert — Dr. Wanda Austin joins as Al Gore departs

Dr. Wanda Austin has joined Apple's board of directors, while former U.S. VP Al Gore has departed.

iMore

Strength in Tech Stocks Powers the Overall Market Higher

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +1.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +2.11%. Stocks on Monday settled moderately higher, with the...

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Stocks Mostly Higher on Strength in Tech and a Decline in Bond Yields

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.51%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.20%. Stocks this morning are mixed, with the Dow Jones...

Barchart

Markets Today: Stocks Climb on M&A Activity and Lower Bond Yields

Morning Markets March E-Mini S&P 500 futures (ES H24) are up +0.06%, and March Nasdaq 100 E-Mini futures (NQH2 4) are up +0.18%. Stock index futures this morning are moderately higher. An increase in M&A activity supports stocks after Boston Scientific agreed to buy Axionics for $3.7 billion and Johnson...

Barchart

Will Matthew Perry’s death spell the end of the ketamine wellness industry?

The actor’s autopsy revealed he had died from taking ketamine, currently being touted as a miracle treatment for mental health problems

The Guardian - US

In 2023, opioid settlement funds flowed to states. Here's how it's going

Some $1.5 billion flowed to local government coffers this year, sparking debates about transparency and how to spend the money. Here are 5 takeaways from a year's worth of reporting on the issue.

WEKU

Read news from The Economist, FT, and more,
with one subscription

3 Solid Pharma Stocks for a Healthy Year-End Portfolio

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

StockNews.com

A CEO contender left Johnson & Johnson. Was she penalized for saying she wanted the job?

The exit of a Johnson & Johnson exec raises an age-old question about women's ambition.

Fortune

His dad worked on the factory floor at Johnson & Johnson. Now he’s the CFO

Joe Wolk, with J&J for over 25 years, talks about his path and the company's focus on innovation.

Fortune

Breakthrough antidepressants with fewer side effects could help millions of Americans. Here's what the future of treatment may look like

As Americans are increasingly reaching for pharmaceutical solutions for depression—about one in eight U.S. adults takes antidepressants—scientists have been innovating novel treatments for it.

Fortune

Should You Invest in Johnson & Johnson (JNJ) Following Q3 Results

Johnson & Johnson’s (JNJ) third-quarter results impressed investors, as its earnings and revenue beat Wall Street estimates. Should investors consider investing in the stock following the solid third-quarter results? Read on to learn my view….

StockNews.com

3 Dividend Aristocrats to Defend Your Portfolio in Q4

In the midst of economic uncertainty, look to the likes of Procter & Gamble, Coca-Cola, and Johnson & Johnson as steadfast investment options, offering relative stability and reliable income for Q4 2023 and beyond.

Barchart

How big companies from EY to Johnson & Johnson are learning to master AI prompts

Embracing AI is the easy part—firms have already moved on to harder parts like making AI actually work for their business.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

Fortune

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

Barchart

Three Stocks To Help You Through the Financial Roller Coaster!

The Middle East is back in focus as tensions broke. But, what can investors own to weather the storm?

USA Today Sports Media Group

Travis Kelce shakes off Aaron Rodgers dig: ‘I’m fully comfortable with him calling me Mr. Pfizer’

Mr. Pfizer and his mustache are doing just fine.

Get all your
news in one place.

100's of premium titles.
One news app.

Sports Illustrated

Chiefs’ Travis Kelce Responds to Aaron Rodgers’s ‘Mr. Pfizer’ Jab

“Who knew I’d get into the vax wars with Aaron Rodgers, man?”

USA Today Sports Media Group

Aaron Rodgers oddly called Travis Kelce ‘Mr. Pfizer’ despite playing for the Johnson & Johnson heir

Aaron Rodgers can be such a dork, man.

Fortune

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

Barchart

Johnson & Johnson Stock Looks Like Good Value Now

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

Barchart

Protect Your Returns With These 3 Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart

Protect Your Returns With These Three Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

AAP

Lawyers lose in better deal for pelvic mesh victims

A law firm that ran two class actions for women harmed by pelvic mesh implants will lose out on a $38.5 million cut of $405 million in settlement funds.

1 … 10 11 12 13

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.